Edition:
India

Crinetics Pharmaceuticals Inc (CRNX.OQ)

CRNX.OQ on NASDAQ Stock Exchange Global Select Market

15.77USD
18 Sep 2020
Change (% chg)

$-0.33 (-2.05%)
Prev Close
$16.10
Open
$16.28
Day's High
$16.28
Day's Low
$15.65
Volume
111,975
Avg. Vol
73,208
52-wk High
$26.65
52-wk Low
$10.63

Select another date:

Thu, Jul 9 2020

BRIEF-Crinetics Pharmaceuticals Receives Orphan Drug Designation For Paltusotine

* CRINETICS PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR PALTUSOTINE FOR THE TREATMENT OF ACROMEGALY Source text for Eikon: Further company coverage:

BRIEF-Crinetics Confirms Completion For Half Of Enrolled Patients In Ongoing Phase 2 Acrobat Edge Clinical Trial For Paltusotine

* CRINETICS PHARMACEUTICALS CONFIRMS COMPLETION FOR HALF OF THE ENROLLED PATIENTS IN THE ONGOING PHASE 2 ACROBAT EDGE CLINICAL TRIAL FOR PALTUSOTINE Source text for Eikon: Further company coverage:

BRIEF-Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results And Provides Corporate Update

* CRINETICS PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Crinetics Pharmaceuticals Prices Public Offering Of 7.15 Mln Common Stock

* CRINETICS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Crinetics Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* CRINETICS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Crinetics Pharmaceuticals Reports Positive Interim Results For Acrobat Edge Phase 2 Trial Of Paltusotine In Acromegaly Patients

* CRINETICS PHARMACEUTICALS REPORTS POSITIVE INTERIM RESULTS FOR THE ACROBAT EDGE PHASE 2 TRIAL OF PALTUSOTINE (CRN00808) IN ACROMEGALY PATIENTS AND PROVIDES CORPORATE UPDATE

Select another date: